BRAF and melanoma: For example, using tumor samples from melanoma patients, Das et al. [71] demonstrated that a combination of crizotinib and a tyrosine kinase inhibitor, afatinib, reduced melanoma tumor growth, regardless of BRAF/NRAS mutational status.